drugset / Trial / NCT00790400

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

NCT00790400 ↗

Phase 3 Completed 118 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.

Timeline

Start
2009-04
Primary completion
2011-06
Completion
2015-11

Outcome

Met primary endpoint

registry analysis (superiority or other test); Everolimus Randomized (Core Period) vs Placebo Randomized (Core Period); p <0.0001; Clopper-Pearson NCT00790400 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 10 mg Oral